BAY 87-2243 is primarily used in research settings to study its effects on hypoxia-inducible factor (HIF) pathways. It has shown potential in inhibiting HIF-1α, which plays a critical role in cellular responses to low oxygen levels. This mechanism makes it a candidate for investigating therapeutic strategies in conditions like cancer, where HIF-1α is often overexpressed and contributes to tumor growth and survival. Researchers are exploring its application in preclinical models to understand its efficacy in disrupting tumor angiogenesis and metabolism. Additionally, it is being studied for its potential in treating diseases related to hypoxia, such as ischemic disorders. Its use remains experimental, with ongoing studies focusing on its safety and therapeutic potential.